|
|
 |
|
Viewing report
|
|
|
|
Thought Leader Insight & Analysis Report: Pain/Analgesics Q3 2010
Medpredict, July 2010, Pages: 134
This report summarizes the consensus findings from six US based anesthesiologists. This elite group identifies unmet needs in the treatment of acute and chronic pain, shares their current favorite approaches to managing pain, and surveys the clinical development pipeline. The report is not meant to list all analgesics, approved or in the pipeline. Rather, it captures our panelists’ ranking of the most medically meaningful therapies that are in the works. This report is divided into five sections: General Findings, Devices, On-Market/Established Mechanisms, Early Pipeline, and Less Likely to Work.
The On-Market section captures some thoughts on opioids, SNRI, GABA and COX2 approaches. Opioids remain the standard of care for the management of severe pain, both acute and chronic. The panel addresses the balance between meeting this medical need and the non-medical ramifications associated with addiction and diversion. In the chronic setting constipation is a major drawback of opioid use. In both the chronic and acute settings, there is also a concern over life threatening respiratory depression. Panelists talk about their favorite new approaches to mitigate, in particular, the respiratory toxicity.
In the Early Pipeline section, the reader will find comments on nerve growth factor antibodies, ampakines, sodium channel blockers, cathepsin K antagonists, compliment antagonists (C5a), calcitonin gene related peptide receptor antagonists, NMDA antagonists and cannabinoids
(CB-1).
On the “Less Likely to Work” front, our panelists suggest approaches that have not panned out, or that are likely to have class related toxicities that should give pause to companies trying to develop new agents. These included: TRPV1 / vanilloids, Substance P/NK-1 and sodium channel blockers.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
